Multidrug Resistance-Associated Proteins

A sequence-related subfamily of ATP-BINDING CASSETTE TRANSPORTERS that actively transport organic substrates. Although considered organic anion transporters, a subset of proteins in this family have also been shown to convey drug resistance to neutral organic drugs. Their cellular function may have clinical significance for CHEMOTHERAPY in that they transport a variety of ANTINEOPLASTIC AGENTS. Overexpression of proteins in this class by NEOPLASMS is considered a possible mechanism in the development of multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although similar in function to P-GLYCOPROTEINS, the proteins in this class share little sequence homology to the ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 family of proteins.

Also Known As:

Networked: 701 relevant articles (7 outcomes, 73 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Aleksunes, Lauren M: 11 articles (10/2022 - 02/2006)
2.	Scheffer, George L: 10 articles (04/2012 - 12/2002)
3.	Qin, Zifei: 8 articles (09/2020 - 03/2018)
4.	Sugiyama, Yuichi: 8 articles (01/2016 - 01/2007)
5.	Manautou, José E: 7 articles (01/2021 - 02/2006)
6.	Yao, Xinsheng: 7 articles (09/2020 - 03/2018)
7.	Yao, Zhihong: 7 articles (09/2020 - 03/2018)
8.	Gonzalez, Frank J: 7 articles (08/2020 - 12/2010)
9.	Klaassen, Curtis D: 7 articles (10/2019 - 05/2006)
10.	Schuetz, John D: 6 articles (08/2021 - 04/2004)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2006 - "The present study aims to provide an update of multidrug resistance in tumor cells and, in particular, of multidrug resistance-associated proteins." 10/27/2004 - "Studies focusing on the transcriptional regulation of MRP7 (multidrug resistance associated protein 7) gene expression in human tumor cells are described. " 01/01/2023 - "Low Pi stress has been shown to inhibit tumor growth and the expression of multidrug resistance-associated proteins. " 11/01/2013 - "The expression of a multispecific organic anion transporter, OATP1B3/SLCO1B3, is associated with clinical prognosis and survival of cancer cells. " 01/01/2013 - "Overexpression of multidrug resistance-associated proteins (MRPs) in tumor cells is a major cause of the intrinsic multidrug resistance phenotype. "
2.	Breast Neoplasms (Breast Cancer) 01/01/1998 - "Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer." 01/01/1997 - "The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer." 10/01/2011 - "Recent in vitro studies demonstrated that EEG is transported by multidrug resistance-associated protein (MRP) 2 and MRP3 and EES is a breast cancer resistance protein (BCRP) substrate. " 01/01/2022 - "Finally,CTNS-/-cells showed reduced apical transport activity in the microfibers compared to healthy PT epithelial cells when looking at breast cancer resistance protein and multidrug resistance-associated protein 4. Engineered PT incorporated in a custom-designed microfluidic chip allowed to assess leak-tightness of the epithelium, which appeared less tight inCTNS-/-PT compared to healthy PT, in agreement with itsin vivophenotype. " 10/15/2021 - "Also, the expression of P-gp, breast cancer resistance protein, and multidrug resistance-associated protein 4 was upregulated by CDDP. "
3.	Drug-Related Side Effects and Adverse Reactions 12/01/1998 - "Major research challenges include the following: (1) the genetic variation of drug targets (receptors, enzymes, etc.), drug transporters (multispecific organic anion transporter, P-glycoprotein, alpha-1-acid glycoprotein, etc.), and drug-metabolizing enzymes (cytochrome P450s and other enzymes); (2) the structure and function of all genetic variants of drug receptors, transporters, and metabolizing enzymes; (3) the induction, repression, and inhibition of all components involved in drug disposition; (4) the development of noninvasive in vivo methods to determine the physiological significance of various components in the handling of specific therapeutic agents in humans; (5) the mechanism of idiosyncratic adverse drug reactions; and (6) the pharmacokinetic and pharmacodynamic relationships to explain the individual differences in therapeutic efficacy and drug safety. "
4.	Rheumatoid Arthritis 04/01/2012 - "Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis."
5.	Lung Neoplasms (Lung Cancer) 01/01/2017 - "IDM, conjugated to CSO, may inhibit the efflux of cellular uptaken DOX via multidrug resistance-associated protein (MRP) and subsequently augment the anti-proliferation potentials of DOX in A549 cells (MRP-expressed human lung cancer cells). " 09/26/1997 - "The multidrug resistance-associated protein (MRP), mediating a multidrug resistance (MDR) phenotype, has been reported to be overexpressed in several drug-selected lung cancer cell lines. " 09/01/1997 - "Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells." 01/01/1997 - "The multidrug resistance-associated protein (MRP) gene is thought to play an important role in MDR in lung cancer. " 07/01/1996 - "Multidrug resistance-associated protein (MRP) gene expression in human lung cancer."

Related Drugs and Biologics

1.	Member 1 Subfamily B ATP Binding Cassette Transporter
2.	Proteins (Proteins, Gene)
3.	ATP-Binding Cassette Transporters (ABC Transporters)
4.	major vault protein
5.	Adenosine Triphosphate (ATP)
6.	Enzymes
7.	Glutathione S-Transferase pi
8.	Cytochromes
9.	Metallothionein
10.	Silybin (Lagosa)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Adjuvant Chemotherapy
4.	Microspheres (Microsphere)
5.	Art Therapy